TY - JOUR
T1 - Engineering the Microbiome to Prevent Adverse Events
T2 - Challenges and Opportunities
AU - Khan, Saad
AU - Hauptman, Ruth
AU - Kelly, Libusha
N1 - Publisher Copyright:
© 2021 by Annual Reviews. All rights reserved.
PY - 2021/1/6
Y1 - 2021/1/6
N2 - In the past decade of microbiome research, we have learned about numerous adverse interactions between the microbiome and medical interventions such as drugs, radiation, and surgery. What if we could alter our microbiomes to prevent these events? In this review, we discuss potential routes to mitigate microbiome adverse events, including applications from the emerging field of microbiome engineering. We highlight cases where the microbiome acts directly on a treatment, such as via differential drug metabolism, and cases where a treatment directly harms the microbiome, such as in radiation therapy. Understanding and preventing microbiome adverse events is a difficult challenge that will require a data-driven approach involving causal statistics, multiomics techniques, and a personalized means of mitigating adverse events. We propose research considerations to encourage productive work in preventing microbiome adverse events, and we highlight the many challenges and opportunities that await.
AB - In the past decade of microbiome research, we have learned about numerous adverse interactions between the microbiome and medical interventions such as drugs, radiation, and surgery. What if we could alter our microbiomes to prevent these events? In this review, we discuss potential routes to mitigate microbiome adverse events, including applications from the emerging field of microbiome engineering. We highlight cases where the microbiome acts directly on a treatment, such as via differential drug metabolism, and cases where a treatment directly harms the microbiome, such as in radiation therapy. Understanding and preventing microbiome adverse events is a difficult challenge that will require a data-driven approach involving causal statistics, multiomics techniques, and a personalized means of mitigating adverse events. We propose research considerations to encourage productive work in preventing microbiome adverse events, and we highlight the many challenges and opportunities that await.
KW - Microbiome engineering
KW - adverse drug response
KW - causal inference
KW - metagenomics
KW - microbiome adverse event
KW - personalized medicine
UR - http://www.scopus.com/inward/record.url?scp=85099137622&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099137622&partnerID=8YFLogxK
U2 - 10.1146/annurev-pharmtox-031620-031509
DO - 10.1146/annurev-pharmtox-031620-031509
M3 - Review article
C2 - 33049161
AN - SCOPUS:85099137622
SN - 0362-1642
VL - 61
SP - 159
EP - 179
JO - Annual Review of Pharmacology and Toxicology
JF - Annual Review of Pharmacology and Toxicology
ER -